Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) spanning five years due to Washington's insistence on confidential biological samples.
This rejection became public after a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman has since stated that the US was requesting genetic material for research and commercial gain but was not willing to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued negotiations to find a agreement agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Context
This development comes after a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US following concerns were raised about the security of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending structures previously established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This framework is designed to guarantee that when a country provides its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration could be designed in a way that respects the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but suggested that talks need to persist since much of the nation's HIV programmes were funded by foreign aid.
"In cases where specific concerns exist, including those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," it commented.
The halted deal highlights the ongoing debate between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.